Pharmaceutical & Life Sciences News

Trump HIV Plan, Gilead Donation Spur Health Center Concerns

Aug. 9, 2019, 9:42 AM

Gilead Sciences Inc.'s donation of enough of its drug Truvada to treat 200,000 people for 10 years comes with some concerns for community health centers that say that it, and funding in President Donald Trump’s HIV plan, could do more harm than good if not distributed properly.

The centers, which provide primary care for underserved communities across the U.S., are a crucial part of Trump’s plan to end the spread of HIV by 2030. They serve about one in five people with HIV, according to George Washington University research, and will likely be a source for patients...

To read the full article log in. To learn more about a subscription click here.